Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -3 of 3
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/21/2008
 
First Published:
10/24/2006
1.
Phase II Study of Trastuzumab (Herceptin®), Cyclophosphamide, and Allogeneic GM-CSF-Secreting Breast Tumor Vaccine in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
JHOC-J05118
JHOC-00001801, JHOC-GT0606190101, JHOC-0605-778, GENENTECH-H3755s, NCT00397371
Last Modified:
1/17/2007
 
First Published:
9/17/2004
2.
Phase I Study of Vaccination Comprising Allogeneic Sargramostim (GM-CSF)-Secreting Breast Cancer Cells With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
NCI
JHOC-J0085
JHOC-RPN-01012502, JHOC-RAC-0304-578, NCT00093834
Last Modified:
10/10/2008
 
First Published:
10/25/2004
3.
Phase I Pilot Study of Vaccine Comprising a HER2/neu-Positive Allogeneic Tumor Cell Line Transfected With the Sargramostim (GM-CSF) Gene in Combination With Low-Dose Interferon alfa and Low-Dose Cyclophosphamide in Women With Stage IV Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other
WRI-GEV-007
NCT00095862, WRI-GEV-007
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute